Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy

Reuters12-01

<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy

Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594388-en) on December 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588847773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588847773","market":"nz","top_or_hot":-1,"title":"Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594388-en) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594388-en) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL28dVVq:1","article_id":"2588847773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588847773","pubTimestamp":1764597376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder . The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board  unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药","CMND":"Clearmind Medicine, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Clearmind Medicine报告酒精使用障碍治疗I/IIa期试验的积极早期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CMND":0.9},"content_text":"Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy\n    \n\nClearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594388-en) on December 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588847773","isCrawlerRequest":true}